At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States:

• New sites in Research Triangle Park and Concord, North Carolina
• New sites at the LEAP Innovation District in Lebanon, Indiana
• Expansions and updates to several different manufacturing facilities in Indianapolis
• Development of the new Lilly Medicine Foundry in Lebanon, Indiana
• Acquisition and expansion of Lilly’s manufacturing site in Kenosha County, Wisconsin

The company is currently negotiating with several states. The company’s previous total domestic capital expansion commitments from 2020 to 2024 totaled $23 billion.

Also Read: Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses

This brings the company’s total U.S. capital expansion commitments to over $50 billion since 2020.

Three of the future U.S. sites announced will focus on manufacturing active pharmaceutical ingredients (APIs), reshoring critical capabilities of small-molecule chemical synthesis, and further strengthening Lilly’s supply chain.

The fourth location will extend the company’s global parenteral manufacturing network for future injectable therapies.

Lilly expects to create more than 3,000 jobs for highly skilled workers at these four new sites, including engineers, scientists, operations personnel, and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites.

“The Tax Cuts and Jobs Act legislation passed in 2017 during President Trump’s first term in office has been foundational to Lilly’s domestic manufacturing investments, and it is essential that these policies are extended this year,” said David Ricks, Lilly chair and CEO.

In May 2024, Eli Lilly more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. 

In October, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.

Price Action: LLY stock is up 1.67% at $916.87 at the last check on Wednesday.

Read Next:

• Budweiser Parent Anheuser-Busch Says ‘Beer Is A Passion Point For Consumers’ On Strong Q4 Performance

Photo by Jonathan Weiss via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

• ELI LILLY (LLY): Free Stock Analysis Report

This article Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.